Related Experiment Video

Updated: May 11, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Glutamic acid and its derivatives: candidates for rational design of anticancer drugs

Imran Ali1, Waseem A Wani, Ashanul Haque

  • 1Department of Chemistry, Jamia Millia Islamia (Central University), New Delhi-110025, India. drimran_ali@yahoo.com

Future Medicinal Chemistry
|May 21, 2013
PubMed

Insights

Glutamic acid derivatives show promise as novel anticancer agents. This review explores their potential in cancer treatment, including drug delivery and mechanisms of action.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Cancer remains a significant global health challenge.
  • Glutamic acid and glutamine are implicated in cancer development.
  • Targeting these amino acids offers a potential therapeutic strategy.

Purpose of the Study:

  • To review the current state of glutamic acid derivatives as anticancer agents.
  • To explore their role in drug delivery systems.
  • To discuss mechanisms, clinical applications, and future directions.

Main Methods:

  • Literature review of existing research on glutamic acid derivatives in cancer.
  • Analysis of studies on glutamic acid-based drug delivery systems.
  • Synthesis of information on mechanisms of action and clinical data.

Main Results:

  • Glutamic acid derivatives demonstrate potential as anticancer agents.
  • Drug delivery systems utilizing glutamic acid show promise.
  • Various mechanisms of action are being investigated.

Conclusions:

  • Glutamic acid derivatives represent a promising area for anticancer drug development.
  • Further research into their mechanisms and clinical applications is warranted.
  • Future development may lead to novel cancer therapies.

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...